CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.
The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies.
“The recommendation to approve Rubraca as monotherapy is welcome news, as once approved it will offer a new treatment option for women with advanced, recurrent ovarian cancer who have BRCA mutant platinum sensitive disease and are unsuitable for platinum based chemotherapy. In this analysis, we observed many women benefiting from extended progression-free survival with acceptable tolerability,” said Dr. Rebecca Kristeleit, Clinical Senior Lecturer and Consultant Medical Oncologist, University College London/University College London Hospitals UK. “These are really important data demonstrating meaningful efficacy and a new non-chemotherapy treatment option for this group of patients who have already been exposed to a number of chemotherapy regimens.”
Ovarian cancer is the sixth deadliest cancer amongst women in Europe, where more than 65,000 women are diagnosed annually.i Ovarian cancer is challenging to treat, and most women will relapse after surgery and chemotherapy. The 80 to 85 percent of women diagnosed in the later stages of the disease (III and IV) have particularly poor outcomes.ii Approximately one in four women with ovarian cancer have a germline or somatic BRCA mutation,iii and new treatment options are needed to treat unique patient populations.
“We are extremely pleased to have received a positive recommendation for approval for Rubraca in an ovarian cancer treatment indication, and we look forward to receiving the formal approval from the European Commission in second quarter 2018,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “This is great news for women living with this difficult disease who often have limited options available. In addition, this opinion from CHMP paves the way for the review of Rubraca in the ovarian cancer maintenance indication, based on the ARIEL3 data. We intend to file a variation to the Marketing Authorization (MA) in June, with a potential recommendation for approval in the broader maintenance indication by the end of 2018.”
Pending approval for the treatment indication, Clovis plans to submit the variation to the MA based on data from the phase 3 ARIEL3 clinical trial, which found that rucaparib significantly improved progression-free survival in all ovarian cancer patient populations studied. ARIEL3 is a double-blind, placebo-controlled trial of rucaparib that enrolled 564 women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer. The primary efficacy analysis evaluated three prospectively defined molecular sub-groups in a step-down manner: 1) BRCA mutant (BRCAmut+); 2) HRD positive (HRD+) inclusive of BRCA mutant; and finally, 3) the intent-to-treat population, or all patients treated in ARIEL3. The study achieved its primary endpoint of improved PFS by investigator review in each of three populations. The variation to the MA will be directed at the broader intent-to-treat or “all comers” population.
About Rubraca ® (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, lung and bladder cancers. Clovis holds worldwide rights for Rubraca.
In the United States, Rubraca is approved on an accelerated basis as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. In December 2017, the U.S. Food and Drug Administration (FDA) accepted the Company’s supplemental New Drug Application (sNDA) for Rubraca for a second-line or later maintenance treatment indication in ovarian cancer based on the ARIEL3 data. The FDA granted Priority Review status to the application with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018.
Rubraca is an unlicensed medical product outside of the U.S.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Please visit clovisoncology.com for more information.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expectation of timing for European Commission approval of rucaparib for the treatment indication and the filing of a variation to the MA for a maintenance indication for rucaparib. Such forward-looking statements involve substantial risks and uncertainties that could cause our future results, performance or achievements to differ significantly from that expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in actions by the FDA, the EMA or other regulatory authorities regarding whether to approve drug applications that may be filed, as well as their decisions that may affect drug labeling, pricing and reimbursement, and other matters that could affect the availability or commercial potential of our drug candidates or companion diagnostics. Clovis Oncology does not undertake to update or revise any forward-looking statements. A further description of risks and uncertainties can be found in Clovis Oncology’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its reports on Form 10-Q and Form 8-K.
i World Health Organization. Globocan 2012: estimated cancer
incidence, mortality and prevalence worldwide in 2012. Accessed 23
ii American Cancer Society. Survival rates for ovarian cancer, by stage. https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html
iii Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775.
Clovis Investor Contacts:
Anna Sussman, 303.625.5022
Breanna Burkart, 303.625.5023
Clovis Media Contacts:
Lisa Guiterman, 301.217.9353
Christy Curran, 615.414.8668
Ann Hughes, +44 (0) 7956 700 790
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
HeartSciences Showcases MyoVista® Wavelet ECG at the 2018 International Congress on Electrocardiology (ICE)25.6.2018 14:00 | Tiedote
HeartSciences, an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018. ICE2018 will be the joint meeting of the 45th Congress of the International Society of Electrocardiology (ISE) and the 18th Congress of the International Society for Holter and Noninvasive Electrocardiology (ISHNE). This Congress will focus on Electrocardiography, from noninvasive diagnosis to prognosis covering basic electrophysiology, novel signal processing methods of Holter ECG, prognostic ECG techniques for preventing sudden cardiac death, applications of antiarrhythmic agents and direct oral anticoagulants, a critical role of catheter ablation for tachyarrhythmias and appropriate use of implantable devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005026/en
OTC Exchange Network Acquires Ogg Trading25.6.2018 14:00 | Tiedote
OTC Exchange Network, Inc. ("OTCXN"), a blockchain-powered capital markets infrastructure company, today announced that it has acquired Ogg Trading, LLC (“Ogg Trading”), a provider of advanced institutional trading technology. The transaction closed June 18, 2018. The acquisition creates a unique and powerful digital asset trading network designed to serve increasing numbers of world-class institutional customers. OTCXN emerges from the transaction with unsurpassed blockchain-powered trading capabilities that provide institutional traders scalability, reliability, compliance and speed. OTCXN provides market participants with measurably lower levels of financial risk, higher levels of certainty, and demonstrable cryptographic provability. Joining OTCXN are Ogg Trading founder David Ogg and Chief Technology Officer Rutie Zhou. An esteemed industry veteran with extensive experience in capital markets, Mr. Ogg previously served as founder and CEO of Hotspot FX (now BATS/CBOE); founder and
Off on Holiday with Mytyres.co.uk – but Safe25.6.2018 12:00 | Tiedote
Summertime is holiday time. And the car is still the main means of transport that families use to get to their holiday destination. This is why responsible drivers should place great importance on their own safety – and that of their passengers. One of the simplest and most effective measures is to start preparations as early as possible. If you pack, load and leave early enough, you won’t need to race and you’ll arrive relaxed. It’s also helpful to give the vehicle the once over at least one week before departure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005265/en/ The brakes should be in proper working order and the oil, coolant and brake fluid levels should all be checked. The windscreen washer reservoir should also be refilled. When fully loaded, the headlamps must also be adjusted – a good opportunity to consult the manual again. If the total weight of the vehicle increases due to the heavy luggage and sever
Tokenization under the EU Regulations with Smartlands Will Define the Future of Investment Banking25.6.2018 11:00 | Tiedote
The volatile nature of the cryptocurrency market is the largest threat that keeps a majority of investors away from the industry, and many businesses from wide adoption of blockchain. The Smartlands Platform solves this challenge by creating the necessary legal framework to enforce assets tokenization in full compliance with the law. Smartlands is going to employ a crowdfunding platform license to create a solid foundation for the future of assets tokenization within the platform. In order to be fully compliant with the law, the company plans further expansion by launching a new office in Vilnius. Asset-backed tokens issued on Smartlands, under crowdfunding platform license, will be sold as securities. The tokens will combine the advantages of blockchain technology and classical investment instruments. They will be in compliance with the legislation of the European Union, provide greater protection for investors, and will be a secure tool to attract investments for companies, whilst pr
Lenovo Attains Status as Largest Global Provider of TOP500 Supercomputers25.6.2018 10:01 | Tiedote
Today, at the International Supercomputing Conference (ISC) in Frankfurt, Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY) continued its global momentum, becoming the world’s largest TOP500 supercomputing provider measured by the number of systems ranked on the TOP500 list. 117 of the 500 most powerful supercomputers included in the TOP500 are Lenovo installations, meaning nearly one out of every four systems (23.4 percent) on the prestigious list is a Lenovo solution. “Last year, we set a goal to become the world’s largest provider of TOP500 computing systems by 2020. We have reached that goal two years ahead of our original plan,” said Kirk Skaugen, President of Lenovo Data Center Group. “This distinction is a testament to our commitment to prioritize customer satisfaction, deliver cutting edge innovation and performance and be the world’s most trusted data center partner. We are motivated every day by the scientists and their groundbreaking research as we work together to solve hum
Enterprise DevOps for the Cloud25.6.2018 10:00 | Tiedote
XebiaLabs, the recognized leader in enterprise DevOps and Continuous Delivery software, today announced a DevOps framework that provides a smooth pathway to the cloud for companies who are moving applications to cloud-based resources on a large scale. The framework connects enterprise DevOps practices with common cloud management functionality and provides an essential foundation as enterprises accelerate their transformations to cloud-based applications. Cloud Does Not Equal DevOps Easy access to public cloud technologies creates a common misconception: moving to the cloud will not only provide more flexible and scalable infrastructure at a lower cost, but it will also accelerate the delivery of applications to the customer. In reality, moving to the cloud is just one step in that journey. Enterprises that are looking to improve and accelerate software delivery are implementing DevOps practices that span the entire software delivery value stream. These practices are generally unrelate
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme